



**THE FOUNDATION
FOR SECURE
MARKETS**

#45771

DATE: OCTOBER 7, 2019

SUBJECT: ALLERGAN PLC - ANTICIPATED ADJUSTMENT
OPTION SYMBOL: AGN
NEW SYMBOL: ABBV1
FUTURES SYMBOL: AGN1D
NEW SYMBOL: AGN2D
DATE: ???

Contract Adjustment

DATE: Effective the opening of the business day after the merger is consummated. Contract adjustment is anticipated to occur by early 2020.

OPTION SYMBOL: AGN changes to ABBV1

STRIKE DIVISOR: 1

CONTRACTS MULTIPLIER: 1

NEW MULTIPLIER: 100 (e.g., a premium of 1.50 yields \$150; a strike of 20 yields \$2,000.00)

NEW DELIVERABLE PER CONTRACT:

- 1) 86 AbbVie, Inc. (ABBV) Common Shares, subject to adjustment as described in the AGN/ABBV Proxy Statement/Prospectus dated September 16, 2019 (“Proxy”)
- 2) Cash in lieu of 0.60 fractional ABBV Common Shares, subject to adjustment as described in the Proxy
- 3) \$12,030.00 Cash (\$120.30 x 100), subject to adjustment as described in the Proxy

CUSIP: ABBV: 00287Y109

PRICING

Until the cash in lieu amount, if any, is determined, the underlying price for ABBV1 will be determined as follows if the terms are unchanged:

$$\text{ABBV1} = 0.8660 (\text{ABBV}) + 120.30$$

DELAYED SETTLEMENT

OCC will delay settlement of the ABBV component and the cash portion of the ABBV1 deliverable until the final merger consideration and cash in lieu amount, if any, are determined. Upon determination of the final merger consideration and cash in lieu amount, if any, OCC will require Put exercisers and Call assignees to deliver the appropriate number of ABBV shares and the appropriate cash amount.

Futures Contract Adjustment

DATE: Effective the opening of the business day after the merger is consummated.
Contract adjustment is anticipated to occur by early 2020.

FUTURES SYMBOL: AGN1D changes to AGN2D

Note: All Allergan Plc (AGN) futures active at the time of the contract adjustment will be adjusted in a similar manner to that of AGN1D futures.

NUMBER OF CONTRACTS: No Change

MULTIPLIER 100 (e.g., a premium of 1.50 yields \$150)

NEW DELIVERABLE PER CONTRACT: 1) 86 AbbVie, Inc. (ABBV) Common Shares, subject to adjustment as described in the Proxy
2) Cash in lieu of 0.60 fractional ABBV Common Shares, subject to adjustment as described in the Proxy
3) \$12,030.00 Cash (\$120.30 x 100), subject to adjustment as described in the Proxy

CUSIP: ABBV: 00287Y109

PRICING

Until the final merger consideration and cash in lieu amount, if any, are determined, the underlying price for the AGN2D Futures contract deliverables, expressed in term of current market value, would be calculated as follows:

$$\text{AGN2D} = 0.8660 (\text{ABBV}) + 120.30$$

Please note that the valuation would apply only to the AGN2D/all active AGN futures deliverables in terms of current market value of the deliverable securities. The resulting price would not be equivalent to the daily settlement price of a futures contract month, whose determination would include cost of money carrying charges, adjustment for dividends, and other factors.

DELAYED SETTLEMENT

OCC will delay settlement of the ABBV component and the cash portion of the AGN2D deliverable until the final merger consideration and cash in lieu amount, if any, are determined. Upon determination of the final merger consideration and cash in lieu amount, if any, OCC will require Put exercisers and Call assignees to deliver the appropriate number of ABBV shares and the appropriate cash amount.

BACKGROUND

On October 14, 2019, Shareholders of Allergan Plc (AGN) will vote concerning the proposed Scheme of Arrangement with AbbVie, Inc. (ABBV). If the merger is approved and consummated, each existing AGN Ordinary Share will be converted into the right to receive 0.8660 ABBV Common Shares plus \$120.30 Cash, subject to adjustment as described in the AGN/ABBV Proxy Statement/Prospectus dated September 16, 2019.

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 4, or 4A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

ALL CLEARING MEMBERS ARE REQUESTED TO IMMEDIATELY ADVISE ALL BRANCH OFFICES AND CORRESPONDENTS ON THE ABOVE.

For questions regarding this memo, call Investor Services at 1-888-678-4667 or email investorservices@theocc.com. Clearing Members may contact Member Services at 1-800-544-6091 or, within Canada, at 1-800-424-7320, or email memberservices@theocc.com.